Rajendra Singh, GlaxoSmithKline

GlaxoSmithKline
Rajendra Singh primarily supports HIV therapeutic area and applies clinical pharmacology and pharmacometric skills in decision making. He supports both early and late phases of clinical development and provides input for dose selection, DDI and study design using PK-PD and translational approaches.

Presenter Of 1 Presentation

Oral abstract session

OAB0706 - Plasma exposure-viral load response analysis for dolutegravir in children with HIV-1: Results from IMPAACT P1093

Room
Abstract Sessions On-Demand Channel

Presenter Of 1 Presentation

Oral abstract session

Plasma exposure-viral load response analysis for dolutegravir in children with HIV-1: Results from IMPAACT P1093

Room
Abstract Sessions On-Demand Channel

Presenter Of 1 Presentation

Oral abstract session

Plasma exposure-viral load response analysis for dolutegravir in children with HIV-1: Results from IMPAACT P1093

Room
Abstract Sessions On-Demand Channel